| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances with that of classic drugs.
It further eliminates the criteria based on the number of doses to distinguish between consumers and traffickers, yet aims to differentiate one from the other so that the former can receive treatment at a time when psychiatric hospitalization due to problematic use of synthetic drugs has spiked. Read more HERE.
UC-San Diego authors assessed psilocybin therapy’s potential as a treatment for anorexia nervosa. They recently shared what are believed to be the first results from such a research study and the findings look promising.
Published in the Nature Medicine journal, the open-label study outcomes reveal COMPASS Pathways (NASDAQ:CMPS) synthetic psilocybin COMP360 treatment as a potential therapy for anorexia nervosa. Read more HERE.
MindBio Therapeutics Corp. has started selection of participants for its phase 2 randomized double-blind and placebo controlled clinical trial in advanced stage cancer patients using microdoses of lysergic acid diethylamide (LSD) and meaning centered psychotherapy in an LSD take-home 6-week trial involving a total of 40 participants.
Patients with a stage IV solid tumor cancer and experiencing emotional distress will be randomized into the trial. Centered psychotherapy is a psychotherapeutic intervention in advanced cancer patients with symptoms of anxiety and or depression. Read more HERE.
The Californians for Treatments, Research, Education, Access and Therapies (TREAT) for Psychedelic Assisted Therapy and Cures officially filed a proposal creating a $5 billion state agency to fund and promote psychedelics research to the state’s attorney general for its potential inclusion in the 2024 ballot this July 19.
“TREAT California is not a direct decriminalization or legalization effort; and it is not an initiative driven by an elected official,” it reads. “Rather, it is a path for citizens to authorize legislative change.” Read more HERE.
Small Pharma’s (OTC:DMTTF) Q1 2024 permeates its revamping strategy and a potential fast-tracked clinical trial.
Societal CDMO (NASDAQ:SCTL) nabbed a Schedule 1 manufacturing license and is set to begin psychedelics production.
Cybin (NYSE:CYBN), Bright Minds (NASDAQ:DRUG) and PharmAla Biotech (OTC:PMBHF) have provided updates on their clinical trials progresses.
Awakn Life Sciences (OTC:AWKNF) is on track with a Phase 3 trial on Substance Use Disorder.
Psychedelic therapy training platform Fluence inked a deal to bring Brazil's scene to new heights.
In Congress, House has greenlighted a bill that would allow VA doctors to recommend medical marijuana and further enhance psychedelics research.
Read about Psychedelic Medicine Coalition CEO Melissa Lavasani’s take on psychedelics advocacy on Capitol Hill.
Singapore executed a woman for heroin possession: Why do punitive drug approaches persist worldwide?
Learn about Fireside Project’s vision and funding model for harm reduction.
Antidepressants vs. psilocybin, a new paper explores how people process emotions on each one.
Unmasking fake LSD: The dangers of 25I-NBOME disguised as acid.
See Ric Flair-inspired vape cartridges, mini bongs & more new cannabis products hitting stores.
Rick Doblin was honored with the Honey Badger Award for fearless psychedelic advocacy at Psychedelic Science 2023.
See Also: Last Week's Edition Of 'Psyched'
AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, July 31 at $1.98, a slight uptake as of prior opening on July 24, at $1.94 and also of Friday 28’s closing at $1.96. During the morning, the number dropped to $1.97, after which it picked to $2.00 and finally closed at $2.01.
Week’s lowest was $1.88 on Thursday 27 (vs. lowest at $1.95 the prior week) and highest was $1.98 on Tuesday 25 (vs. prior week’s $2.06).
The ETF’s yearly price range is set between $4.35 and $1.65.
GH Research (NASDAQ:GHRS) closed at $13.15 today, a 6.54% daily down.
COMPASS Pathways (NASDAQ:CMPS) closed at $9.32 today, a 2.53% daily increase.
Mind Medicine (MindMed) (NASDAQ:MNMD) closed at $4.93, up 13.07% today.
Bright Minds Biosciences (NASDAQ:DRUG) closed at $4.16 today, up 5.32%.
Enveric Biosciences (NASDAQ:ENVB) closed at $2.73 today, up 11.43%.
Silo Pharma (NASDAQ:SILO) closed at $2.14, a 1.42% daily increase.
atai Life Sciences (NASDAQ:ATAI) closed at $2.09 today, a daily 1.46% increase
Incannex Healthcare (NASDAQ:IXHL) closed at $1.89, a 2.69% daily fall.
Seelos Therapeutics (NASDAQ:SEEL) closed at $1.53, on a 1.53% increase.
FSD Pharma (NASDAQ:HUGE) closed at $1.17, a daily 7.34% jump.
Lucy Scientific (NASDAQ:LSDI) closed at $1.10, a 2.80% daily increase.
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Posted In: ATAI AWKNF CMPS CYBN DMTTF DRUG ENVB GHRS HUGE IXHL LSDI MNMD PMBHF PSIL SCTL SEEL SILO
